Keep pulling the thread on Sacha Schermerhorn.
The Alzheimer's drug Aducanumab reduced amyloid PET imaging signals by approximately 76% but showed no impact on patient cognition.
Biomarker data indicates that amyloid plaques begin to deposit in the brain 20 to 30 years before the onset of Alzheimer's symptoms.
The biomarker p-tau217, a fragment of tau tangles, is the single most predictive marker for when an individual will develop the cognitive impairment phase of Alzheimer's disease.
Babylon Bio's strategy involves acquiring and developing shelved pharmaceutical assets that could generate exits in the low nine-figure range to self-finance its primary Alzheimer's research.
Sacha Schermerhorn predicts that BIIB080, an intrathecally delivered tau ASO from Biogen and Ionis, will be the most efficacious drug for Alzheimer's to date.
The FDA advisory committee for Biogen's Aducanumab, consisting of 14 members, unanimously rejected the drug's approval, yet it was still submitted for approval.
Trontinimab is an antibody therapeutic that hijacks the transferrin receptor to increase its transport across the blood-brain barrier, resulting in the best amyloid clearance efficacy seen to date.
Pfizer acquired Biohaven for $11.6 billion after Biohaven successfully developed Rimegepant, a migraine drug it had licensed from Bristol Myers Squibb.
Babylon Bio is collaborating with OpenAI to fine-tune models that can predict clinical trial outcomes, using the binary success or failure of trials as a loss function to train the models on biological reasoning.
A study in Wales found that individuals who received the shingles vaccine were 20% less likely to develop Alzheimer's disease or all-cause dementia within a seven-year period.
Babylon Bio was founded with the mission of finding a cure for Alzheimer's disease.
Approximately half of all research funding for Alzheimer's disease has been spent on the amyloid cascade hypothesis.